Login to Your Account


Hard-fought approval to commercial flop: Uniqure pulling plug on first gene therapy

By Nuala Moran
Staff Writer

Friday, April 21, 2017

LONDON – Uniqure NV is ditching its world-first gene therapy Glybera and will not renew the European license when it expires on Oct. 25. If that is a sad end to one of the most protracted drug development sagas in history, it undoubtedly sets a bad precedent for expensive one-off therapies coming through the pipeline – for which Uniqure's persistence with the EMA did so much to forge the way.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription